1822-PUB: Identifying the Link between In-Hospital Hyperglycemia and Outcomes among Persons Admitted with a Severe Infection

Abstract

Background: Hyperglycemia is common among hospitalized patients and is associated with suboptimal outcomes. We investigated the impact of hyperglycemia in persons admitted with severe infection (diagnosis of infection according to the treating physician combined with either ≥2 qSOFA-criteria or ≥2 SIRS-criteria) with and without diabetes. Methods: We prospectively recruited people with a severe infection into this observational study and applied a blinded glucose sensor. No changes were made to usual care. Results: Here, we present preliminary data from 48 persons (expected recruitment n=200) : 67% male, age 63±17 y). 29% had known diabetes. Urinary (20%), airway (8%), and skin (8%) were the most common infection foci; three persons died during admission. Among all, the mean glucose was 140±64 mg/dL, with hyperglycemia present in 36 (75%) persons (Figure 1). Figure 1 shows the 24h sensor profiles for all (panel A), persons with (panel B) and without diabetes (panel C). Mean glucose was 205 (±75) vs 113 (±33) in people with and without known diabetes. Similarly time in range (70-180 mg/dl) was 11 vs 77% in people with and without diabetes. 18% of those with no known diabetes had >10% time above range (>180 mg/dl) Conclusion: Hyperglycemia was a frequent finding. We will evaluate the link between sensor-measured glycemic parameters, blood values and detailed outcome data using the Acutelines biobank. Disclosure J.J.Bakker: None. A.Van der vaart: None. H.Bouma: None. P.Choudhary: Advisory Panel; Medtronic, Novo Nordisk, Dexcom, Inc., MannKind Corporation, Insulet Corporation, Research Support; Abbott Diabetes, Speaker's Bureau; Sanofi, Lilly. P.Van dijk: None.